Survival Rates for Prostate Cancer
Survival rates of prostate cancer are based on outcomes of people who’ve had the disease. Find the survival rates for prostate cancer here.
Related Articles
AUA 2025: Efficacy and Safety of Darolutamide Plus Androgen-Deprivation Therapy (ADT) in Black Patients With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) from the Phase 3 ARANOTE Trial
AUA 2025 ARANOTE trial (NCT04736199), ad hoc analysis of the phase III ARANOTE trial, efficacy and safety of darolutamide + ADT in black patients with…
AUA 2025: State-of-the-Art Lecture: Urothelial Markers
AUA 2025 State-of-the-Art Lecture on Urothelial Markers, biomarkers for urothelial cancer, Tissue based biomarkers, RETAIN-2 trial, membranous Nectin-4 in urothelial cancer, CxBladder.
AUA 2025: Whitmore Lecture: The Evolving Role of Surgery for Bladder Cancer – The Surgeon can Make a Difference
AUA 2025, Bladder Cancer, Evolving Role of Surgery for Bladder Cancer, robot-assisted radical cystectomy (RARC) open radical cystectomy (ORC), a standard pelvic lymph node dissection…
AUA 2025: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer: ENLIGHTED Phase 3 Study
AUA 2025 phase 3 ENLIGHTED study, padeliporfin vascular targeted photodynamic (VTP) therapy for treatment of low-grade upper tract urothelial cancer.
AUA 2025: Long-Term Outcomes of Treatment of Recurrent or New-Onset Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel
AUA 2025 phase 3 OLYMPUS trial, UGN-101, low-grade upper tract urothelial carcinoma, upper tract urothelial carcinoma tumor recurrence, uTRACT registry (NCT05874921).
AUA 2025: Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Upfront Cytoreductive Nephrectom, Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma, CARMENA trial,
AUA 2025: Performance of Minimal Residual Disease Detection with Urine-Derived DNA in High-Grade Bladder Cancer Patients Undergoing Recommended Repeat Transurethral Resection
AUA 2025 performance of minimal residual disease detection with urine-derived DNA, high-grade bladder cancer, recommended repeat TURBT, UroAmp.
AUA 2025: Evaluating the Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT in a Prospective Cohort
AUA 2025, prostate cancer, 18F-DCFPyL, 18F-FDG PET/CT, Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT imaging.
AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
AUA 2025: Primary Resistance to Nivolumab plus Ipilimumab Therapy Affects Second-Line Treatment Outcomes in Patients with mRCC
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus…